Balchem (NASDAQ:BCPC) Stock Price Down 84.7% - Should You Sell?

Balchem Corporation (NASDAQ:BCPC - Get Free Report) fell 84.7% during trading on Monday . The stock traded as low as $152.42 and last traded at $23.86. 113,134 shares traded hands during mid-day trading, a decline of 20% from the average session volume of 141,227 shares. The stock had previously closed at $156.01.

Analyst Ratings Changes

Several research firms recently commented on BCPC. Wall Street Zen lowered shares of Balchem from a "buy" rating to a "hold" rating in a report on Wednesday, May 21st. HC Wainwright set a $180.00 price target on shares of Balchem and gave the company a "buy" rating in a report on Monday, April 28th.

Balchem Price Performance

The company has a debt-to-equity ratio of 0.18, a current ratio of 2.44 and a quick ratio of 1.40. The company's 50-day simple moving average is $162.79 and its 200-day simple moving average is $163.65. The company has a market cap of $5.18 billion, a price-to-earnings ratio of 38.06, a P/E/G ratio of 3.41 and a beta of 0.91.

Balchem (NASDAQ:BCPC - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The basic materials company reported $1.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.25 by ($0.03). Balchem had a net margin of 14.16% and a return on equity of 12.01%. The firm had revenue of $250.52 million during the quarter, compared to analyst estimates of $245.70 million. During the same period last year, the business earned $1.03 EPS. The firm's revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts anticipate that Balchem Corporation will post 4.64 EPS for the current year.

Institutional Trading of Balchem

A number of hedge funds have recently made changes to their positions in BCPC. Norges Bank acquired a new stake in shares of Balchem during the fourth quarter worth approximately $70,165,000. Nuveen LLC acquired a new stake in shares of Balchem during the first quarter worth approximately $47,214,000. GAMMA Investing LLC grew its position in shares of Balchem by 20,231.2% during the first quarter. GAMMA Investing LLC now owns 177,288 shares of the basic materials company's stock worth $29,430,000 after buying an additional 176,416 shares in the last quarter. Millennium Management LLC grew its position in shares of Balchem by 660.5% during the first quarter. Millennium Management LLC now owns 195,525 shares of the basic materials company's stock worth $32,457,000 after buying an additional 169,816 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Balchem during the fourth quarter worth approximately $23,628,000. Institutional investors and hedge funds own 87.91% of the company's stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.